http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010003705-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f684eff5de5b62e83fe5088e81160e8a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7267964b3c49c4c23aaf45920d14d967 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e27f2955d5025436872d8c3a21a6ee63 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2009-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b34bb238b5aa6a69b1b84fc36090a1f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ab4c256dc1c922dd80aa18d7b8e1a04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9d47363f6160c3ed57fa130434f2b16 |
| publicationDate | 2010-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2010003705-A1 |
| titleOfInvention | Cln101 Antibody Compositions and Methods of Use Alone and in Combination with Prostate Specific Antigen and Other Cancer Markers |
| abstract | This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Cln101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Cln101 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (Cln101) antibodies that bind to Cln101 in vivo. The invention also encompasses compositions comprising an anti-Cln101 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Cln101 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Cln101 antibodies. The invention encompasses a method of producing the anti-Cln101 antibodies. Other aspects of the invention are a method of killing an Cln101-expressing cancer cell, comprising contacting the cancer cell with an anti-Cln101 antibody and a method of alleviating or treating an Cln101-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Cln101 antibody to the mammal. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013126147-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3064945-A1 |
| priorityDate | 2003-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 860.